Literature DB >> 17168656

Targeting signaling pathways in multiple myeloma.

Cavallo Federica1, Palumbo Antonio, Tricot Guido, Boccadoro Mario.   

Abstract

Multiple myeloma (MM) is an incurable malignancy of terminally differentiated B-cells accounting for approximately 1 to 2% of all human cancers. The development of MM is believed to be a multistep transformation process that leads to progressive accumulation of genetic alterations. The interaction between MM and bone marrow (BM) microenviroment triggers multiple proliferative and antiapoptotic signaling pathways. Here we discuss the current understanding of signaling pathways, and their potential implication in targeted therapies in MM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17168656     DOI: 10.2174/138920106779116883

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  2 in total

1.  Frontal skull craniotomy combined with moderate-dose radiotherapy effectively ameliorate a rare case of non-secretory, multiple myeloma with orbital involvement.

Authors:  Hui-Ling Ko; Ching-Lin Chen; Kwan-Hwa Chi
Journal:  World J Surg Oncol       Date:  2009-11-12       Impact factor: 2.754

2.  An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.

Authors:  Pradip De; Nandini Dey; Breanne Terakedis; P Leif Bergsagel; Zhi Hua Li; Daruka Mahadevan; Joseph R Garlich; Suzanne Trudel; Milan T Makale; Donald L Durden
Journal:  Cancer Chemother Pharmacol       Date:  2013-01-25       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.